Based on the Puma Biotechnology Inc stock forecast from 2 analysts, the average analyst target price for Puma Biotechnology Inc is USD 6.25 over the next 12 months. Puma Biotechnology Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Puma Biotechnology Inc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Puma Biotechnology Inc’s stock price was USD 2.90. Puma Biotechnology Inc’s stock price has changed by -7.64% over the past week, -18.08% over the past month and -48.76% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for Puma Biotechnology Inc
No recent average analyst rating found for Puma Biotechnology Inc
Company Overview Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. Read Less
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with ...Read More
Frequently Asked Questions About Puma Biotechnology Inc (PBYI) Stock
Based on ratings from 2 analysts Puma Biotechnology Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on PBYI's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for PBYI is USD 6.25 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 4.
PBYI stock's Price/Earning ratio is 5.06.
Our analysis grades PBYI stock's Price / Earning ratio at F. This means that PBYI stock's Price/Earning ratio is above 49% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PBYI may be fairly valued for its sector
The last closing price of PBYI's stock was USD 2.90.
The most recent market capitalization for PBYI is USD 0.16B.
Based on targets from 2 analysts, the average taret price for PBYI is projected at USD 6.25 over the next 12 months.
This means that PBYI's stock price may go up by +115.52% over the next 12 months.
We can't find any ETFs which contains Puma Biotechnology Inc's stock.
As per our most recent records Puma Biotechnology Inc has 172 Employees.
Puma Biotechnology Inc's registered address is 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024.
You can get more information about it from Puma Biotechnology Inc's website at https://www.pumabiotechnology.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Puma Biotechnology Inc (PBYI) Stock
Based on ratings from 2 analysts Puma Biotechnology Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on PBYI's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for PBYI is USD 6.25 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 4.
PBYI stock's Price/Earning ratio is 5.06.
Our analysis grades PBYI stock's Price / Earning ratio at F. This means that PBYI stock's Price/Earning ratio is above 49% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PBYI may be fairly valued for its sector
The last closing price of PBYI's stock was USD 2.90.
The most recent market capitalization for PBYI is USD 0.16B.
Based on targets from 2 analysts, the average taret price for PBYI is projected at USD 6.25 over the next 12 months.
This means that PBYI's stock price may go up by +115.52% over the next 12 months.
We can't find any ETFs which contains Puma Biotechnology Inc's stock.
As per our most recent records Puma Biotechnology Inc has 172 Employees.
Puma Biotechnology Inc's registered address is 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024.
You can get more information about it from Puma Biotechnology Inc's website at https://www.pumabiotechnology.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PBYI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
